Finally, the results raise the question of whether interventions that are already guideline-endorsed for cardiovascular and renal protection, such as SGLT2 inhibitors, renin-angiotensin system blockade, and comprehensive heart-failure therapies, can deliver measurable improvements in KCCQ scores when applied specifically in hypertensive diabetics. Here, SLC5A2 is linked to heart failure.